Creation of an Indian subsidiary and the opening of an office in India.

Macopharma SA (“Macopharma”), an innovator in global healthcare and provider of transfusion, infusion and cellular therapy products and solutions, is proud to announce the creation of a new subsidiary in India.

The opening of an office in New Delhi, is a strategic initiative in order to promote our products and technology all over the Asian area.

 

The official address in India is :

Macopharma India Transfusion Solution Pvt. Ltd.

DLF Tower A, 6th floor, Unit 617, N.H. Commercial Centre Jasola
New-Delhi 110025
Tel : +91 11 -4209 1900 / Fax : +91 11-4209 1999
Mobile : +91 98 1056 5080
mannoj.panwar@macopharma.com

 

This subsidiary will offer Macopharma a competitive advantage on the challenging market to increase our sales and partnership meanwhile to reinforce our global presence in the world of transfusion.
Mr Mannoj Panwar, will establish the infrastructure for the subsidiary and eventually will assemble his team to assist him in the development of this market.

 

ABOUT MACOPHARMA SA

Macopharma SA (“Macopharma”) (www.macopharma.com) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. It has become the largest supplier of in-line leucoreduction filtration sets in Europe and is expanding its efforts into the cellular therapy field by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), Macopharma has three manufacturing facilities in Europe and their products are sold into more than 55 countries worldwide. One of Macopharma’s aims is to provide a comprehensive range for the pathogen reduction of infectious agents in plasma, platelets and red cells. This is aligned with the Macopharma’s product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion and cellular therapy

Véronique Lutun – Communication Manager
 

« Go back to the list